Schatzberg AF
Stanford University Mood Disorders Center and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA.
ArticleKetamine
Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.
ArticleKetamine
Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
ArticleKetamine
Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment.
ArticleKetamine
Ketamine/esketamine treatment for resistant depression in children and adolescents: a PRISMA systematic review.
ArticleKetamine
Esketamine Treatment for Depression in Adults: Response to Price et al. and Canuso et al.
ArticleKetamine
Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.
ArticleKetamine
Methodological considerations for interpreting ketamine-naltrexone trials in depression.
ArticleKetamine
Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.
ArticleKetamine
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
ArticleKetamine
Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?
ArticlePsilocybin
The Black Book of Psychotropic Dosing and Monitoring.
ArticleKetamine